Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF CANCER
Volume 133, Issue 2, Pages 307-314
Publisher
Wiley
Online
2013-01-21
DOI
10.1002/ijc.28046
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
- (2012) Astrid A.M. Van der Veldt et al. CANCER CELL
- Vascular and Metabolic Response to Bevacizumab-Containing Regimens in Two Patients With Colorectal Liver Metastases Measured by Dynamic Contrast-Enhanced MRI and Dynamic 18F-FDG-PET
- (2012) Dennis Vriens et al. Clinical Colorectal Cancer
- Effects of Anti-VEGF on Pharmacokinetics, Biodistribution, and Tumor Penetration of Trastuzumab in a Preclinical Breast Cancer Model
- (2012) C. V. Pastuskovas et al. MOLECULAR CANCER THERAPEUTICS
- EGFR- and VEGF(R)-Targeted Small Molecules Show Synergistic Activity in Colorectal Cancer Models Refractory to Combinations of Monoclonal Antibodies
- (2011) V. Poindessous et al. CLINICAL CANCER RESEARCH
- Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer
- (2011) Leonard Saltz et al. Clinical Colorectal Cancer
- Cetuximab after bevacizumab in metastatic colorectal cancer: Is it the best sequence?
- (2011) Emmanuelle Norguet et al. DIGESTIVE AND LIVER DISEASE
- Radiolabeled cetuximab: Dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model
- (2010) Bianca A.W. Hoeben et al. INTERNATIONAL JOURNAL OF CANCER
- ImmunoSPECT and ImmunoPET of IGF-1R Expression with the Radiolabeled Antibody R1507 in a Triple-Negative Breast Cancer Model
- (2010) S. Heskamp et al. JOURNAL OF NUCLEAR MEDICINE
- 111In-Bevacizumab Imaging of Renal Cell Cancer and Evaluation of Neoadjuvant Treatment with the Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib
- (2010) I. M. E. Desar et al. JOURNAL OF NUCLEAR MEDICINE
- Investigation of the efficacy of a bevacizumab-cetuximab-cisplatin regimen in treating head and neck squamous cell carcinoma in mice
- (2010) Yixiang Wang et al. Targeted Oncology
- U-SPECT-II: An Ultra-High-Resolution Device for Molecular Small-Animal Imaging
- (2009) F. van der Have et al. JOURNAL OF NUCLEAR MEDICINE
- Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
- (2009) Jolien Tol et al. NEW ENGLAND JOURNAL OF MEDICINE
- FDA Drug Approval Summary: Bevacizumab (Avastin(R)) as Treatment of Recurrent Glioblastoma Multiforme
- (2009) M. H. Cohen et al. ONCOLOGIST
- Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Cancer Cells
- (2008) R. Bianco et al. CLINICAL CANCER RESEARCH
- A Randomized Phase IIIB Trial of Chemotherapy, Bevacizumab, and Panitumumab Compared With Chemotherapy and Bevacizumab Alone for Metastatic Colorectal Cancer
- (2008) J. Randolph Hecht et al. JOURNAL OF CLINICAL ONCOLOGY
- Therapeutic Targeting of Neuropilin-2 on Colorectal Carcinoma Cells Implanted in the Murine Liver
- (2008) M. J. Gray et al. JNCI-Journal of the National Cancer Institute
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now